Adults with uncontrolled asthma may benefit from a three-in-one inhaler that adds a long-acting muscarinic receptor antagonist to LABA-ICS, researchers say.

European doctors have conducted two randomised controlled trials of the novel, single-inhaler triple therapy that contains the LAMA glycopyrronium plus formoterol and beclomethasone, finding that patients using it had 12-15% fewer exacerbations.